AstraZeneca said Dec. 11 that it will begin a clinical trial of its COVID-19 vaccine in combination with Russia's COVID-19 vaccine before the end of the year.
The trial will enroll volunteers 18 years and older.
Preliminary results have shown Russia's Sputnik V vaccine to be 90 percent effective in preventing COVID-19 infection, according to The Hill. Russia authorized the vaccine in August, the first country to do so. It began vaccinating people this week.
Read AstraZeneca's full news release here.
Subscribe to the following topics: covid-19coronaviruspharmacyvaccineclinical trial